Sernova Biotherapeutics Inc (SEOVF)
OTCMKTS · Delayed Price · Currency is USD
0.1415
+0.0095 (7.20%)
Jul 25, 2025, 11:21 AM EDT
Sernova Biotherapeutics Employees
Sernova Biotherapeutics had 17 employees as of October 31, 2024.
Employees
17
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$994,071
Market Cap
49.15M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Oct 31, 2024 | 17 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Endo, Inc. | 3,116 |
| Tian'an Technology Group | 8 |
| Elite Pharmaceuticals | 68 |
| Glass House Brands | 374 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 9 |
| American Oncology Network | 1,914 |
| Silence Therapeutics | 116 |
Sernova Biotherapeutics News
- 17 days ago - Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes - GlobeNewsWire
- 7 weeks ago - Sernova Appoints Jonathan Rigby as Interim Chair - GlobeNewsWire
- 2 months ago - Chair of Sernova Biotherapeutics Resigns - GlobeNewsWire
- 2 months ago - Sernova Biotherapeutics Appoints World-Class Clinical Advisory Board to Support Development of Cell Pouch Bio-hybrid Organ as Functional Cure for Type 1 Diabetes - GlobeNewsWire
- 2 months ago - Sernova Biotherapeutics Provides Positive Interim Data from Ongoing Phase 1/2 Clinical Trial of Cell Pouch Bio-hybrid Organ in Patients Living with Type 1 Diabetes - GlobeNewsWire
- 3 months ago - Sernova Biotherapeutics Secures $4 Million Loan to Further Advance its Clinical Development Plans - GlobeNewsWire
- 3 months ago - Sernova Biotherapeutics Cell Pouch Bio-hybrid Organ to be Highlighted at Cell & Gene Meeting on the Med - GlobeNewsWire
- 4 months ago - Sernova Biotherapeutics Provides Update on Phase 1/2 Clinical Trial of Cell Pouch™ Bio-Hybrid Organ for Treatment of Type 1 Diabetes - GlobeNewsWire